期刊文献+

高效液相色谱-质谱法测定注射用磺苄西林钠中D(-)型磺苄西林钠的含量 被引量:1

Determination of D(- ) Sulbenicillin Sodium in Sulbenicillin Sodium for Injection by HPLC-MS
原文传递
导出
摘要 目的 建立高效液相色谱串联质谱法测定注射用磺苄西林钠中D(-)型磺苄西林钠含量的方法。方法 采用SHIMADZu VP-ODS色谱柱进行分离,以0.01 mol·L-1乙酸铵溶液-甲醇(90∶10)为流动相,流速为0.6 mL·min-1。在ESI负离子模式下,采用多反应离子监测(MRM)扫描方式进行检测。结果 D(-)型及L(+)型磺苄西林钠能够有效分离。D(-)型磺苄西林钠含量在1.03~51.90 μg·mL-1内与峰面积有良好的线性关系。在3个添加水平下,样品的加标回收率为99.98%,测定结果的相对标准偏差为0.30%(n=9)。结论 MRM方法定量准确、可靠,可用于注射用磺苄西林钠中D(-)型磺苄西林钠的含量检测。 To establish a method for determination of D(-) sulbenicillin sodium in sulbenicillin sodium for injection by HPLC/MS. METHODS The analysis was performed on a SHIMADZU VP-ODS column with mobile phase consisting of 0.01 mol·L-1 ammonium acetate solution-methanol (90∶10) at a flow rate of 0.6 mL·min-1. The detection was performed by Multiple Reaction Monitoring (MRM) scanning mode with ESI negative ion mode. RESULTS D(-) and L(+) sulbenicillin could be effectively separated. Good liner relationship was achieved when the concentration of D(-) sulbenicillin was in the range of 1.03-51.90 μg·mL-1(r=0.999 7). The average recovery rate was 99.98% at three levels (RSD=0.30%, n=9). CONCLUSION The MRM method is accurate, reliable, and can be used for the determination of D(-) sulbenicillin sodium in sulbenicillin sodium for injection.
出处 《中国药学杂志》 CAS CSCD 北大核心 2013年第22期1951-1954,共4页 Chinese Pharmaceutical Journal
基金 科技部"国家工程技术研究中心"组建资助项目(2012FU125Q13)
关键词 液质联用 注射用磺苄西林钠 D(-)型磺苄西林钠 含量测定 HPLC-MS sulbenicillin sodium for injection D( - ) sulbenicillin quantitative analysis
  • 相关文献

参考文献3

二级参考文献41

  • 1国家药典委员会.《中国药典》2005年版二部[s].北京:化学工业出版社,2005,正文品种:856.
  • 2日本药局方编辑委员会.《日本药局方》15版[S].official monographs:1123-1124.
  • 3Duncan M W,Hunsucker S W.Proteomics as a tool for clinically relevant biomarker discovery and validation[J].Exp Biol Med (Maywood),2005,230(11):808-817.
  • 4Veenstra T D,Conrads T P,Hood B L,et al.Biomarkers:mining the biofluid proteome[J].Mol Cell Proteomics,2005,4(4):409-418.
  • 5Rifai N,Gillette M A,Carr S A.Protein biomarker discovery and validation:the long and uncertain path to clinical utility[J].Nat Biotechnol,2006,24(8):971-983.
  • 6Domon B,Aebersold R.Mass spectrometry and protein analysis[J].Science,2006,312(5771):212-217.
  • 7Orvisky E,Drake S K,Martin B M,et al.Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma[J].Proteomics,2006,6(9):2895-2902.
  • 8Anderson N L,Anderson N G.The human plasma proteome:history,character,and diagnostic prospects[J].Mol Cell Proteomics,2002,1(11):845-867.
  • 9Kuhn E,Wu J,Karl J,et al.Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards[J].Proteomics,2004,4(4):1175-1186.
  • 10Barnidge D R,Goodmanson M K,Klee G G,et al.Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-Ms/MS using protein cleavage and isotope dilution mass spectrometry[J].J Proteome Res,2004,3(3):644-653.

共引文献9

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部